{
    "nct_id": "NCT05654623",
    "official_title": "A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE (VERITAC-2)",
    "inclusion_criteria": "* Adult participants with loco-regional recurrent or metastatic breast disease not amenable to surgical resection or radiation therapy\n* Confirmed diagnosis of ER+/HER2- breast cancer\n* Prior therapies for locoregional recurrent or metastatic disease must fulfill all the following criteria:\n* One line of CDK4/6 inhibitor therapy in combination with endocrine therapy. Only one line of CDK4/6 inhibitor is allowed in any setting.\n* ≤ 1 endocrine therapy in addition to CDK4/6 inhibitor with ET\n* Most recent endocrine treatment duration must have been given for ≥6 months prior to disease progression. This may be the endocrine treatment component of the CDK4/6 inhibitor line of therapy.\n* Radiological progression during or after the last line of therapy.\n* Measurable disease evaluable per Response Evaluation Criterion in Solid Tumors (RECIST) v.1.1 or non-measurable bone-only disease\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Participants should be willing to provide blood and tumor tissue\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participants with advanced, symptomatic visceral spread, that are at risk of life-threatening complications in the short term\n* Prior treatment with:\n* ARV-471, fulvestrant, elacestrant, mTOR, PI3K, AKT pathway inhibitors, PARP inhibitor for any setting\n* other investigational agents (including novel endocrine therapy any SERDs, SERCAs, CERANs) for any setting\n* prior chemotherapy for advanced/metastatic disease\n* Inadequate liver, kidney and bone marrow function\n* Active brain metastases\n* Participants with significant concomitant illness",
    "miscellaneous_criteria": ""
}